14-[[3-chloro-5-(trifluoromethyl)phenyl]carbamoylamino]tetradecanoic acid

14-[[3-chloro-5-(trifluoromethyl)phenyl]carbamoylamino]tetradecanoic acid, also known as compound 7d, is a synthetic aryl-urea fatty acid derivative developed as a mitochondrial-targeting anticancer agent. It belongs to a series of lipid-based molecules designed to exploit the unique mitochondrial characteristics of cancer cells. The drug's mechanism of action involves the disruption of the mitochondrial membrane potential ($Δψ_m$), which leads to the overproduction of reactive oxygen species (ROS) and the subsequent induction of apoptosis. Research has demonstrated that the carbon chain length of these aryl-urea fatty acids is a critical determinant of their biological activity, with the C14 analogue (7d) showing significant potency in disrupting mitochondrial function and killing breast cancer cells, such as the MDA-MB-231 line. It was developed as part of a structure-activity relationship study to identify optimal leads for mitochondrial-directed chemotherapy.

Other names

C14 aryl-urea fatty acidC-14 aryl-urea fatty acidC 14 aryl-urea fatty acid